Logo-bma
Biomed Advances. 2025;2(1): 10-24. doi: 10.34172/bma.10

Review Article

Therapeutic effects of NK cell-derived EVs on cancer: Current advances and future treatment strategies

Mehtap Kizilpinar 1 ORCID, Mohammadreza Dastouri 2 * ORCID

Cited by CrossRef: 0

1- Mangang N, Gargasz S, Murugan S, Kumar M, Shukla G, Vijayaraghavalu S. MicroRNAs Modulating Cancer Immunotherapy Mechanisms and Therapeutic Synergies. Cancers. 2025;17(24):3978 [Crossref]
2- Nathani A, Padakanti S, Dev S, Singh M. The electrical and chemical hypoxia-optimized (ECHO) bioreactor system enables scalable production of functionally preserved NK-exosomes validated in a syngeneic lung cancer model. Drug Deliv and Transl Res. 2026; [Crossref]

Acceptance Rate: 35%
Submission to First Decision: 20 Days
Received to Acceptance: 60 Days
Acceptance to Publication: 40 Days
*Average article statistics from the last 12 months of data.

In collaboration with